1. | 20forMSFT | |
2. | vstarknox | |
3. | JasonJohnJacobs | |
4. | cogvos6 | |
5. | sspd94 |
1. | 20forMSFT | |
2. | vstarknox | |
3. | JasonJohnJacobs | |
4. | cogvos6 | |
5. | sspd94 |
1. | JasonJohnJacobs 03/11/2018 4 sure |
2. | JasonJohnJacobs 01/22/2018 Downgrade not hurting us at all |
3. | JasonJohnJacobs 08/03/2018 Beats EPS loss estimates by $0.01 |
4. | JasonJohnJacobs 10/18/2017 Panic in the streets |
5. | JasonJohnJacobs 08/27/2018 Esperion Announces Positive Top-Line Results from Pivotal Phase 3 Bempedoic Acid / Ezetimibe Combination Pill Study |
6. | 20forMSFT 06/13/2018 Esperion Announces Late-Breaking Oral Presentation of Full Study 4 Results (1002-048) at the International Symposium on Atherosclerosis |
7. | vstarknox 03/11/2018 WOW! |
8. | vstarknox 03/27/2018 Esperion Announces Positive Top-Line Results from Phase 2 Study of Bempedoic Acid Added-On to a PCSK9 Inhibitor in Patients with Hypercholesterolemia |
9. | 20forMSFT 10/18/2017 Thought company said today would be a big day? |